GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Microbot Medical Inc (FRA:CY9D) » Definitions » Debt-to-EBITDA

Microbot Medical (FRA:CY9D) Debt-to-EBITDA : -0.01 (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Microbot Medical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Microbot Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.06 Mil. Microbot Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.03 Mil. Microbot Medical's annualized EBITDA for the quarter that ended in Sep. 2024 was €-11.81 Mil. Microbot Medical's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Microbot Medical's Debt-to-EBITDA or its related term are showing as below:

FRA:CY9D' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.51   Med: -0.08   Max: -0.01
Current: -0.01

During the past 13 years, the highest Debt-to-EBITDA Ratio of Microbot Medical was -0.01. The lowest was -0.51. And the median was -0.08.

FRA:CY9D's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.54 vs FRA:CY9D: -0.01

Microbot Medical Debt-to-EBITDA Historical Data

The historical data trend for Microbot Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbot Medical Debt-to-EBITDA Chart

Microbot Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -0.09 -0.06 -0.04 -0.02

Microbot Medical Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.03 -0.02 -0.02 -0.01

Competitive Comparison of Microbot Medical's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Microbot Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbot Medical's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Microbot Medical's Debt-to-EBITDA falls into.



Microbot Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Microbot Medical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.175 + 0.037) / -9.198
=-0.02

Microbot Medical's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.059 + 0.026) / -11.812
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Microbot Medical  (FRA:CY9D) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Microbot Medical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Microbot Medical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbot Medical Business Description

Traded in Other Exchanges
Address
288 Grove Street, Suite 388, Braintree, MA, USA, 02184
Microbot Medical Inc is a pre-clinical medical device company. It specializes in developing next-generation micro-robotic medical technologies that can change the future of medicine. Their vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures and offer physicians and their patients less invasive and more precise solutions. The company's innovative platforms LIBERTY and Self-Cleaning Shunt (SCS) are in one of the fastest-growing segments in healthcare. The group continuously develops its technology with the goal to improve surgical outcomes worldwide. The firm presently holds domestic and global patents that strengthen its product portfolio and create barriers of entry.

Microbot Medical Headlines

No Headlines